FINWIRES · TerminalLIVE
FINWIRES

Singapore Shares Extend Loss as US-Iran Talks Stall; Addvalue Technologies Surges 36%

By

Singapore shares remained in the red zone on Monday amid stalled U.S.-Iran peace negotiations.

The Straits Times Index (STI), a key benchmark for the Singapore Exchange, ranged between 4,885.96 and 4,925.71 throughout the day. It ended the session at 4,892.73, down 30.13 points or 0.6% compared to Friday's close.

In economic news, Singapore's manufacturing output jumped 10.1% in March, backed by strong growth across almost all clusters, according to the city-state's Department of Statistics.

On the corporate front, shares of Addvalue Technologies (SGX:A31) zoomed over 36% at the close as the company filed an application to the SGX-ST for a proposed spin-off of its Inter-Satellite Data Relay System business on Nasdaq.

Mooreast's (SGX:1V3) shares closed over 6% higher as its subsidiary, Mooreast Asia, granted HLMG-Nuform System an option to purchase its leasehold property in Singapore for SG$29.7 million.

Meanwhile, shares of MoneyMax Financial Services (SGX:5WJ) were up nearly 3% at the close as it raised around SG$43.4 million through the issuance of shares.

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA